RNA-Seq vs qPCR: Validation and Comparison

RNA sequencing (RNA-Seq) and quantitative polymerase chain reaction (qPCR) are two distinct approaches for measuring gene expression, and they serve complementary roles in the laboratory. RNA-Seq provides genome-wide discovery of differentially expressed genes, while qPCR offers targeted, cost-effective confirmation of specific transcripts. The practical question for most researchers is not which method is superior but how to use both effectively in a single workflow. This article explains when to use each technique, how to validate RNA-Seq results with qPCR, and which factors determine whether the two methods will agree.

At a Glance: RNA-Seq and qPCR Compared

The choice between RNA-Seq and qPCR depends on the research question, sample availability, budget, and the need for discovery versus confirmation. Many published studies use RNA-Seq for initial screening and qPCR for validation of candidate genes in independent cohorts.

Core Principles of Gene Expression Measurement

What RNA-Seq Measures

RNA-Seq quantifies the complete set of transcripts in a sample by converting RNA to complementary DNA, fragmenting it, and sequencing the fragments. The number of reads mapping to each gene provides a measure of its expression level. This approach can detect known genes, novel transcripts, splice variants, and non-coding RNAs in a single experiment. The European Bioinformatics Institute provides training materials on RNA-Seq analysis through its official training portal, which covers experimental design, quality control, and data interpretation.

RNA-Seq data require substantial bioinformatics processing. Raw sequencing reads must be quality trimmed, aligned to a reference genome or transcriptome, and quantified. The choice of alignment and quantification tools affects the final gene expression values. Researchers should document the exact software versions and parameters used because these choices influence reproducibility.

What qPCR Measures

Quantitative PCR measures the accumulation of amplified DNA in real time. After reverse transcription of RNA to cDNA, gene-specific primers amplify the target sequence, and a fluorescent probe or dye reports the amount of product after each cycle. The cycle at which fluorescence crosses a threshold, called the Ct value, is inversely related to the starting amount of template. Lower Ct values indicate higher expression.

qPCR is a relative method. Expression levels are typically normalized to reference genes that are assumed to be stable across the conditions being compared. The choice of reference genes is critical because unstable references produce inaccurate results. RNA-Seq data can help identify stable reference genes, but those candidates still require experimental validation by qPCR.

Why the Two Methods Often Agree but Sometimes Do Not

RNA-Seq and qPCR measure the same biological quantity, messenger RNA abundance, so they generally correlate well for moderately and highly expressed genes. However, discrepancies arise from technical differences. RNA-Seq quantifies transcripts through sequencing depth and read counts, while qPCR measures amplification efficiency and fluorescence. Genes with low expression, high sequence similarity to other genes, or complex splicing patterns are more likely to show discordant results between the two methods.

When to Use RNA-Seq

Discovery and Hypothesis Generation

RNA-Seq is the method of choice when the goal is to identify differentially expressed genes without prior knowledge of which genes matter. Studies of disease mechanisms, drug responses, and developmental processes frequently begin with RNA-Seq to generate candidate gene lists. For example, a study of doxorubicin-induced cardiotoxicity used RNA-Seq to identify thousands of dysregulated genes and then narrowed the list to immune-related hub genes for further investigation.

RNA-Seq also detects transcript isoforms and non-coding RNAs, which qPCR cannot easily distinguish unless isoform-specific primers are designed. Long non-coding RNAs have emerged as important regulators in many biological systems, and their discovery depends on sequencing-based approaches.

Complex Experimental Designs

When comparing multiple conditions, time points, or cell types, RNA-Seq provides a comprehensive view of transcriptomic changes. The data can be reanalyzed as new questions arise without repeating the experiment. This flexibility makes RNA-Seq valuable for generating hypotheses that can be tested in follow-up studies.

Sample Types with Limited Prior Information

For organisms without well-annotated genomes or for samples where the relevant transcripts are unknown, RNA-Seq is the only practical approach. Studies in non-model organisms, such as the Chinese mitten crab molting cycle and alfalfa defoliation traits, rely on RNA-Seq to characterize gene expression in the absence of extensive prior data.

When to Use qPCR

Validation of Candidate Genes

The most common use of qPCR in transcriptomic studies is validation of RNA-Seq results. After RNA-Seq identifies differentially expressed genes, qPCR confirms those findings in the same samples or in an independent cohort. This confirmation step is important because RNA-Seq can produce false positives, especially for low-abundance transcripts or genes with alignment ambiguities.

Many published studies follow this two-step approach. A study of metabolic dysfunction-associated steatotic liver disease measured FGF21 expression by both qPCR and RNA-Seq in human liver samples and found significant upregulation by both methods. Similarly, a study of knee osteoarthritis used RNA-Seq to identify sex-related differentially expressed genes in synovium and then validated candidate genes by qPCR in a larger independent cohort.

Large Sample Numbers

When the genes of interest are known and the sample size is large, qPCR is more practical than RNA-Seq. The cost per sample is lower, and the workflow is faster. Clinical validation studies often use qPCR to test candidate biomarkers in hundreds of samples. A colorectal cancer study identified candidate RNA markers through RNA-Seq and then validated them by RT-qPCR in an independent cohort of more than 200 individuals.

Clinical and Diagnostic Applications

qPCR is the standard method for clinical gene expression testing because it is robust, relatively inexpensive, and can be standardized across laboratories. The workflow is simpler than RNA-Seq and does not require high-performance computing resources. For applications where the target genes are well established, qPCR provides reliable results with faster turnaround times.

How to Validate RNA-Seq Results with qPCR

Select Candidate Genes for Validation

Not every differentially expressed gene from RNA-Seq needs qPCR validation. Choose genes based on biological relevance, statistical significance, and expression level. Prioritize genes with large fold changes and low adjusted p-values. Include genes with moderate expression levels because very low abundance genes are difficult to validate reliably by qPCR.

Include both upregulated and downregulated genes in the validation set. This approach tests whether the direction of change is consistent between methods. A study of tuberculosis identified differentially expressed mRNAs by RNA-Seq and confirmed the expression patterns of candidate molecules by RT-qPCR, including both upregulated and downregulated transcripts.

Design Primers with Care

Primer design is the most important technical factor in qPCR validation. Primers should be specific to the target transcript and should not amplify genomic DNA. Design primers that span exon-exon junctions to avoid amplification of contaminating genomic DNA. Verify primer specificity by checking for off-target matches in the reference transcriptome.

For genes with multiple isoforms, decide whether the validation targets all isoforms or a specific isoform. RNA-Seq quantifies all transcripts mapping to a gene unless isoform-level quantification is performed. qPCR primers should match the quantification approach used in the RNA-Seq analysis.

Use the Same RNA Samples

For direct comparison of methods, use the same RNA preparations for both RNA-Seq and qPCR. This approach eliminates biological variation between samples and isolates technical differences between the methods. If independent cohorts are used for validation, the biological variation is expected to be larger, and the concordance between methods may be lower.

Normalize qPCR Data Appropriately

qPCR data must be normalized to reference genes to control for differences in RNA input and reverse transcription efficiency. The choice of reference genes affects the validation outcome. RNA-Seq data can identify candidate reference genes with stable expression across the experimental conditions, but those candidates require experimental validation.

A study in lettuce used RNA-Seq to preselect candidate reference genes for anthocyanin-related gene expression studies and then evaluated their stability by qPCR using multiple analytical tools. The authors recommended different reference genes for different experimental conditions, demonstrating that reference gene stability is context dependent. Similarly, a study in Clostridium beijerinckii selected reference genes based on RNA-Seq data and validated them by RT-qPCR, finding that the most stable genes were suitable for normalization.

Compare Results Using Appropriate Metrics

The simplest comparison between RNA-Seq and qPCR is the direction of change. A gene called upregulated by RNA-Seq should also show increased expression by qPCR. For quantitative comparison, calculate fold changes by both methods and assess correlation. Log-transformed fold changes from RNA-Seq and qPCR can be plotted against each other, and the Pearson or Spearman correlation coefficient provides a measure of agreement.

Do not expect perfect quantitative agreement. RNA-Seq and qPCR use different measurement principles, and fold changes from the two methods often differ by a factor of two or more. The goal of validation is to confirm the direction and approximate magnitude of expression changes, not to reproduce identical values.

Factors Affecting Concordance Between RNA-Seq and qPCR

Gene Expression Level

Highly expressed genes show better concordance between RNA-Seq and qPCR because they have higher read counts and lower technical variability. Lowly expressed genes are more susceptible to noise in both methods. RNA-Seq may fail to detect very low abundance transcripts, while qPCR may produce unreliable Ct values near the detection limit.

Transcript Complexity

Genes with multiple isoforms, overlapping genes, or high sequence similarity to other loci are difficult to quantify accurately by both methods. RNA-Seq read alignment may assign reads ambiguously, and qPCR primers may amplify multiple targets. These genes require careful analysis and may show poor concordance between methods.

Reference Gene Stability

qPCR results depend on the stability of reference genes across the experimental conditions. If reference gene expression changes between groups, the normalized qPCR data will be biased. RNA-Seq can help identify stable reference genes, but the final choice must be validated experimentally. A study in Clostridium beijerinckii demonstrated that RNA-Seq data can guide reference gene selection, but experimental validation by RT-qPCR remains necessary.

Data Analysis Choices

The RNA-Seq analysis pipeline affects the final gene expression values. Different alignment tools, quantification methods, and normalization approaches produce different results. The choice of differential expression analysis method also influences which genes are called significant. These analysis choices should be documented and considered when comparing RNA-Seq results to qPCR.

Biological Variability

When validation is performed in an independent cohort, biological variability between individuals contributes to discordance between RNA-Seq and qPCR results. The validation cohort may have different characteristics than the discovery cohort, such as age, sex, or disease severity. These differences can affect gene expression and reduce the concordance between methods.

Practical Workflow for Combined RNA-Seq and qPCR Studies

Step 1: Define the Research Question

Determine whether the study requires discovery, validation, or both. If the genes of interest are unknown, begin with RNA-Seq. If the genes are known and the question is quantitative, qPCR may be sufficient. Many studies benefit from a combined approach where RNA-Seq provides discovery and qPCR provides confirmation.

Step 2: Design the RNA-Seq Experiment

Consider the number of biological replicates, sequencing depth, and read length. More replicates improve statistical power, while deeper sequencing improves detection of low-abundance transcripts. The experimental design should account for potential confounding factors such as batch effects and sample processing order.

Step 3: Perform RNA-Seq Data Analysis

Process the raw sequencing data through a documented pipeline. Perform quality control, alignment, quantification, and differential expression analysis. Record all software versions and parameters. The National Center for Biotechnology Information provides data resources and tools that support RNA-Seq analysis and data sharing.

Step 4: Select Candidate Genes for qPCR Validation

Choose genes based on biological relevance, statistical significance, and expression level. Include both upregulated and downregulated genes. Consider including genes with different expression levels to test the dynamic range of the validation.

Step 5: Design and Validate qPCR Primers

Design primers that are specific to the target transcripts and that span exon-exon junctions. Test primer efficiency using serial dilutions of cDNA. Verify that the primers produce a single product by melt curve analysis or gel electrophoresis.

Step 6: Perform qPCR Validation

Use the same RNA samples as the RNA-Seq experiment for direct comparison. Include appropriate reference genes and no-template controls. Run all samples in technical replicates and record Ct values.

Step 7: Analyze and Compare Results

Calculate relative expression levels using the delta-delta Ct method or a standard curve. Compare the direction and magnitude of expression changes between RNA-Seq and qPCR. Assess correlation using appropriate statistical methods.

Step 8: Document and Report

Report the RNA-Seq analysis pipeline, qPCR conditions, primer sequences, and reference genes. Include the concordance metrics between methods. Deposit raw data in public repositories where possible. The NIH Genomic Data Sharing Policy describes expectations for data sharing in NIH-funded research, and the FAIR Guiding Principles provide a framework for making data findable, accessible, interoperable, and reusable.

Records and Measurements

What to Record for RNA-Seq

Maintain detailed records of the RNA-Seq experiment, including sample preparation, library construction, sequencing platform, read length, sequencing depth, and quality metrics. Record the bioinformatics pipeline with software versions and parameters. Document the number of reads per sample, alignment rates, and the number of genes detected.

What to Record for qPCR

Record the RNA concentration and quality for each sample, reverse transcription conditions, primer sequences, primer efficiency, and Ct values for all technical replicates. Document the reference genes used and their stability metrics. Record the calculation method for relative expression and the final fold change values.

Concordance Metrics

For each validated gene, record the RNA-Seq fold change, qPCR fold change, and the direction of change by both methods. Calculate the correlation between log-transformed fold changes across all validated genes. Document any genes that show discordant results and investigate the possible causes.

Common Failure Patterns in RNA-Seq and qPCR Validation

Discordant Direction of Change

A gene called upregulated by RNA-Seq but downregulated by qPCR indicates a serious problem. Possible causes include primer design errors, reference gene instability, or misalignment of RNA-Seq reads. Investigate the gene structure and primer locations to identify the source of the discrepancy.

Poor Correlation Between Methods

Even when the direction of change is consistent, the quantitative agreement may be poor. This pattern often results from differences in measurement principles, low expression levels, or high biological variability. Consider whether the discordance is consistent across genes or limited to specific transcripts.

Unstable Reference Genes

If the qPCR results are inconsistent across replicate experiments, the reference genes may be unstable. Re-evaluate reference gene stability using the RNA-Seq data and test alternative candidates. A study in lettuce demonstrated that reference gene stability varies by experimental condition, so the choice of reference genes should be condition specific.

Amplification of Genomic DNA

If qPCR primers do not span exon-exon junctions, they may amplify contaminating genomic DNA, producing inaccurate results. Include a no-reverse-transcriptase control to detect genomic DNA contamination. Redesign primers to span exon-exon junctions if necessary.

Batch Effects in RNA-Seq Data

If RNA-Seq samples are processed in multiple batches, batch effects can introduce systematic variation that obscures true biological differences. Include batch information in the analysis model and consider using computational methods to correct for batch effects.

Limitations of Both Methods

RNA-Seq Limitations

RNA-Seq requires substantial bioinformatics expertise and computing resources. The analysis pipeline is complex, and different choices can produce different results. RNA-Seq is less sensitive than qPCR for detecting very low abundance transcripts. The cost per sample is higher, which limits the number of biological replicates that can be included.

RNA-Seq measures relative abundance, not absolute transcript numbers. The data are compositional, meaning that changes in one gene affect the measured abundance of others. This property must be considered when interpreting differential expression results.

qPCR Limitations

qPCR can only measure known transcripts for which primers have been designed. The method does not discover new genes or isoforms. qPCR is sensitive to primer design errors, reference gene instability, and PCR inhibition. The dynamic range is limited at both the low and high ends of expression.

qPCR is a relative method that requires careful normalization. The choice of reference genes is critical, and inappropriate references produce misleading results. The method is also sensitive to RNA quality and reverse transcription efficiency.

Interpretation Limits

Neither method provides direct evidence of protein abundance. Messenger RNA levels correlate with protein levels for some genes but not others. Post-transcriptional regulation, protein stability, and translational efficiency all affect the relationship between mRNA and protein. Gene expression measurements should be interpreted as transcript abundance, not protein activity.

Quality and Reproducibility Controls

RNA Quality Assessment

Both RNA-Seq and qPCR require high-quality RNA. Assess RNA integrity using an automated electrophoresis system or a similar method. Degraded RNA produces biased results, particularly for genes with long transcripts. Document the RNA quality metrics for all samples.

Technical Replicates

Include technical replicates in qPCR experiments to assess pipetting and amplification variability. Technical replicates should produce Ct values within a narrow range. The number of technical replicates depends on the precision required and the variability of the assay.

Biological Replicates

Biological replicates are essential for both RNA-Seq and qPCR studies. They capture the natural variability between individuals or samples and provide the basis for statistical inference. The number of biological replicates should be determined by the expected effect size and the variability of the system.

Controls

Include appropriate controls in both methods. For qPCR, include no-template controls to detect contamination and no-reverse-transcriptase controls to detect genomic DNA amplification. For RNA-Seq, include spike-in controls if absolute quantification is needed. Document all controls and their results.

Reproducibility Across Experiments

Reproducibility should be assessed by repeating experiments under the same conditions. The FAIR Guiding Principles provide a framework for making research data findable, accessible, interoperable, and reusable, which supports reproducibility across laboratories and studies.

Safety and Regulatory Context

Data Sharing Requirements

Research funded by the NIH is subject to the Genomic Data Sharing Policy, which sets expectations for the sharing of genomic data generated through NIH-funded research. Researchers should be aware of these requirements when planning RNA-Seq studies and should deposit data in appropriate repositories.

Data Repositories

The National Center for Biotechnology Information provides data resources for storing and accessing genomic data, including RNA-Seq datasets. The European Bioinformatics Institute also offers training and data resources for bioinformatics. Depositing data in public repositories supports reproducibility and enables secondary analysis by other researchers.

Ethical Considerations

Gene expression studies involving human samples must comply with ethical and regulatory requirements for human subjects research. Studies involving animal samples must follow institutional animal care and use guidelines. Researchers should obtain appropriate approvals before beginning experiments.

Professional Escalation Criteria

When to Seek Bioinformatics Support

If the RNA-Seq analysis pipeline produces inconsistent results or if the bioinformatics requirements exceed local expertise, seek support from a bioinformatics core facility or collaborator. The European Bioinformatics Institute provides training resources that can help researchers develop the necessary skills.

When to Repeat Experiments

If qPCR validation fails to confirm RNA-Seq results for a substantial proportion of candidate genes, repeat the experiments before drawing conclusions. Investigate the possible causes of discordance, including primer design, reference gene stability, and RNA quality. If the discordance persists, consider whether the RNA-Seq analysis pipeline requires revision.

When to Consult a Statistician

If the statistical analysis of differential expression or validation data is complex, consult a statistician. The choice of statistical methods affects the results, and inappropriate methods can produce misleading conclusions. A statistician can help with experimental design, power calculations, and data analysis.

Frequently Asked Questions

What is the main difference between RNA-Seq and qPCR?

RNA-Seq measures the expression of all genes in a sample through high-throughput sequencing, while qPCR measures the expression of specific target genes through targeted amplification. RNA-Seq is used for discovery and hypothesis generation, while qPCR is used for validation and targeted measurement.

Why is qPCR used to validate RNA-Seq results?

qPCR provides an independent measurement of gene expression using a different technical principle. Confirming RNA-Seq findings by qPCR reduces the risk of false positives and increases confidence in the results. Many journals and reviewers expect qPCR validation of key RNA-Seq findings.

How many genes should be validated by qPCR?

The number of genes selected for validation depends on the study goals and resources. Most studies validate between 5 and 20 genes, prioritizing those with the largest fold changes, strongest statistical significance, and greatest biological relevance. Include both upregulated and downregulated genes.

What causes discordance between RNA-Seq and qPCR results?

Discordance can result from low expression levels, transcript complexity, primer design errors, reference gene instability, and biological variability between cohorts. The two methods use different measurement principles, so some quantitative differences are expected. Investigate the causes when the direction of change is inconsistent.

Can qPCR replace RNA-Seq for gene expression studies?

qPCR cannot replace RNA-Seq for discovery studies because it only measures known transcripts. For targeted measurement of known genes in large sample cohorts, qPCR is often more practical and cost-effective. The choice depends on the research question and the number of genes and samples involved.

How should reference genes be selected for qPCR?

Reference genes should have stable expression across the experimental conditions being compared. RNA-Seq data can identify candidate reference genes with low variation, but those candidates require experimental validation by qPCR. Reference gene stability should be assessed for each experimental context.

What is the cost difference between RNA-Seq and qPCR?

RNA-Seq is generally more expensive per sample than qPCR, especially for deep sequencing or large numbers of samples. The cost difference narrows when many genes are measured per sample. For small gene panels and large sample numbers, qPCR is typically more cost-effective.

How should RNA-Seq and qPCR data be compared?

Compare the direction of change for each gene and calculate the correlation between log-transformed fold changes. The direction of change should be consistent between methods. Quantitative agreement is expected to be approximate instead of exact because the methods use different measurement principles.

Related Bioinformatics Guides

• Alternative Splicing Analysis from RNA-Seq Data
• Single-Cell RNA-Seq Analysis Pipelines for Veterinary Immunology
• RNA Seq Fastq Example: Structural Analysis and Computational Methodologies in Bioinformatics
• RNA-Seq Differential Expression: DESeq2, edgeR, and limma-voom Frameworks
• Gene Ontology (GO) and Enrichment Analysis

References and Further Reading

• EMBL-EBI Training. European Bioinformatics Institute.
• NCBI Data Resources. National Center for Biotechnology Information.
• Genomic Data Sharing Policy. National Institutes of Health.
• The FAIR Guiding Principles. Scientific Data.
• Oxidative stress reprograms benign prostatic hyperplasia microenvironments: insights from integrative multi-omics and machine learning.. Journal of translational medicine, 2026.
• Fibroblast growth factor 21 is a hepatokine involved in MASLD progression.. United European gastroenterology journal, 2024.
• Transcriptomic profiles in Parkinson's disease.. Experimental biology and medicine (Maywood, N.J.), 2021.
• Selection of Novel Reference Genes by RNA-Seq and Their Evaluation for Normalising Real-Time qPCR Expression Data of Anthocyanin-Related Genes in Lettuce and Wild Relatives.. International journal of molecular sciences, 2023.
• Therapeutic effect and mechanisms of traditional Chinese medicine compound (Qilong capsule) in the treatment of ischemic stroke.. Phytomedicine : international journal of phytotherapy and phytopharmacology, 2024.
• Streptococcus gallolyticus supernatant induces M2 macrophage polarization and activates IL-17 F signaling in colorectal tumorigenesis.. Gut pathogens, 2025.
• An Integrated Network Pharmacology and RNA-seq Approach for Exploring the Protective Effect of Isoquercitrin in Doxorubicin-Induced Cardiotoxicity: Identification of Novel Genes.. Cardiovascular toxicology, 2025.
• Identification of Colorectal Cancer-Related RNA Markers from Whole Blood Using Integrated Bioinformatics Analysis.. International journal of molecular sciences, 2025.
• Identification of Candidate mRNA and miRNA Molecules Associated with Tuberculosis Through Preliminary Analysis and Validation Using Clinical Samples. 2026.
• lncRNA-operated stem cell fate control: RPS3 mediates the in situ Gm16751-Zhx3 interactome to program spermatogonial stem cell differentiation.. 2026.
• Identification and experimental validation of CD74, PGLYRP1, and TXN as potential biomarkers in rheumatoid arthritis: an integrative bulk and ScRNA-seq study.. 2026.
• Identification of Candidate mRNA and miRNA Molecules Associated with Tuberculosis Through Preliminary Analysis and Validation Using Clinical Samples.. 2026.
• Long Non-Coding RNAs Identified as Hub Genes by Weighted Gene Co-Expression Network Analysis in &lt,i&gt,Schistosoma mansoni&lt,/i&gt, Following Incubation with &lt,i&gt,Bothrops&lt,/i&gt, Snake Venoms.. 2026.
• Differential Gene Expression in Synovium Between Male and Female Knee Osteoarthritis.. 2026.
• Integrative RNA-seq and iRIP-seq analysis links SNRPA overexpression to transcriptomic and splicing alterations in hepatocellular carcinoma cells.. 2026.
• Suppressed SF3B1 Expression Lowers METTL3 Transcription and m6A RNA Expression. 2026.
• Identification and Validation of Reference Genes in Clostridium beijerinckii NRRL B-598 for RT-qPCR Using RNA-Seq Data. Frontiers in Microbiology, 2021.
• Long non-coding RNA RP11-342L8.2, derived from RNA sequencing and validated via RT-qPCR, is upregulated and correlates with disease severity in psoriasis patients. Irish Journal of Medical Science, 2022.
• miRNA-seq and clinical evaluation in multiple myeloma: miR-181a overexpression predicts short-term disease progression and poor post-treatment outcome. British Journal of Cancer, 2021.
• Deciphering Pro-angiogenic Transcription Factor Profiles in Hypoxic Human Endothelial Cells by Combined Bioinformatics and in vitro Modeling. Frontiers in Cardiovascular Medicine, 2022.
• Integrated Analysis of ATAC-Seq and RNA-Seq Reveals the Signal Transduction Regulation of the Molting Cycle in the Muscle of Chinese Mitten Crab (Eriocheir sinensis). Biomolecules, 2026.
• Study on differentially expressed genes related to defoliation traits in two alfalfa varieties based on RNA-Seq. BMC Genomics, 2018.
• Transcriptomic analysis reveals novel age-independent immunomodulatory proteins as a mode of cerebroprotection in P2X4 receptor knockout mice after ischemic stroke. Purinergic Signalling, 2023.
• RNA-seq analysis of salt-stressed versus non salt-stressed transcriptomes of chenopodium quinoa landrace R49. Genes, 2019.

This article is educational and does not replace validated analysis plans, institutional policy, clinical interpretation, or specialist review.